Skip to main content

Table 2 TDI focal score and SGRQ-C total score after 4 weeks (full analysis set)

From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD

Ensifentrine dose

TDI focal score

SGRQ-C total score

Mean (SD)

Treatment–placebo difference (95% confidence interval); p value

Mean (SD)

Treatment–placebo difference (95% confidence interval); p value

6 mg (N = 80)

1.39 (2.179)

1.11 (0.16 to 2.06); 0.022

41.5 (15.20)

−2.67 (− 6.26 to 0.91); 0.143

3 mg (N = 82)

1.55 (3.436)

1.19 (0.25 to 2.14); 0.014

40.1 (15.93)

−2.29 (−5.96 to 1.37); 0.220

1.5 mg (N = 81)

1.92 (3.221)

1.64 (0.69 to 2.59); 0.001

41.4 (16.24)

−2.85 (−6.46 to 0.76); 0.121

0.75 mg (N = 81)

1.49 (2.810)

1.29 (0.32 to 2.25); 0.009

45.1 (14.95)

−2.22 (−5.87 to 1.42); 0.231

Placebo (N = 79)

0.37 (3.220)

 

43.5 (16.99)

 
  1. Abbreviations: TDI, Transition Dyspnoea Index; SGRQ-C, St George’s Respiratory Questionnaire – Chronic Obstructive Pulmonary Disease Specific